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Induction with T cell-depleting anti-
bodies was used in 83% of recipients,
and 76% of patients received tacro-
limus, mycophenolate, and prednisone
for maintenance immunosuppression.
As ethnicity, duration of dialysis prior
to transplantation, donor source, and
immunosuppression may all impact
outcomes and potentially modify the
effects of diabetes, the results may be
less applicable to programs with largely
non-Caucasian populations, a higher
proportion of deceased donors, longer
waiting times, or different immuno-
suppressive protocols.
The data presented clearly demon-
strate that excellent transplant outcomes
are achievable for a significant propor-
tion of patients with diabetes and
ESKD, and thus diabetes should not
be viewed as a contraindication to
kidney transplantation. Should we then,
on the basis of these data, liberalize
access to transplantation for diabetic
patients with ESKD? The authors, quite
reasonably, suggest we should ‘give
consideration’ to this. In doing so, we
must consider more than just crude
patient survival. Indeed, modeling
studies that have examined incremental
costs and benefits of transplantation vs.
dialysis demonstrate that wait-listing
and giving transplants to patients
with diabetes is highly cost-effective
and prolongs life, relative to non-
listing.7 The impacts of transplan-
tation on recipient quality of life,
carer and family life, cost of care to
society, and opportunity cost for those
not given transplants all warrant close
consideration. Substantial changes to
wait-listing policy and organ allocation
require modeling of data obtained from
registries and cohort studies, informed
by ethical and societal considerations, to
determine the outcomes of those given
and those not given transplants. To this
end, the data provided by Keddis et al.5
make an important contribution.
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Novel evidence on hepatitis C
virus–associated glomerular
disease
Fabrizio Fabrizi1,2, Piergiorgio Messa1 and Paul Martin2
A large spectrum of renal pathology is associated with hepatitis C virus
(HCV). According to novel evidence, occult HCV infection (HCV-RNA in
peripheral blood mononuclear cells or in serum after ultracentrifugation)
could be involved in the pathogenesis of glomerular nephropathy
among patients negative for conventional markers of HCV. Additional
studies with appropriate size and technology are in progress to confirm
the relationship between occult HCV and glomerular disease, which has
multiple implications from the clinical standpoint.
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Hepatitis C virus (HCV) has an esti-
mated prevalence of 3% worldwide
(around 170 million infected indivi-
duals all over the world) and remains
a major global health burden. The
long-term hepatic impact of HCV
infection includes chronic hepatitis,
and cirrhosis, with or without hepato-
cellular carcinoma. Several extrahepatic
manifestations have been associated
with HCV infection, including hema-
tologic, dermatologic, autoimmune,
and kidney diseases. There is increasing
evidence of an association between
HCV infection and glomerular disease
both in native kidneys and after kidney
(or liver) transplantation. The most
common type of HCV-related glomer-
ulonephritis is type I membranoproli-
ferative glomerulonephritis, usually in
the context of type II cryoglobulinemia.
HCV-infected patients show less
common glomerular diseases including
membranoproliferative glomerulone-
phritis without cryoglobulinemia, mem-
branous nephropathy, focal segmental
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sclerosis, mesangial glomerulonephritis,
and fibrillary and immunotactoid glo-
merulopathies. Anecdotal information
has been reported on HCV-associated
IgA nephropathy, and cryoglobulinemic
thrombotic microangiopathy. In addi-
tion to glomerular disease, tubulointer-
stitial injury has been also observed in
association with HCV infection.
The most important survey on
the epidemiology of HCV-associated
glomerular disease has been conducted
by El-Serag et al.1 They carried out a
hospital-based case–control study that
enrolled all cases of HCV-infected
patients hospitalized during the 1990s
(n¼ 34,204) and randomly chosen
control individuals without HCV
(n¼ 136,816) matched with cases on
the year of admission. As expected,
cryoglobulinemia was more common
in cases than controls (0.57 vs. 0.05%,
Po0.0001), and a greater prevalence of
membranoproliferative glomerulone-
phritis (0.36 vs. 0.05%) but not mem-
branous nephropathy (0.33 vs. 0.19%)
was observed in HCV-infected indivi-
duals. A recent meta-analysis of clinical
studies (four clinical studies with 81,286
unique individuals) demonstrated that
HCV-seropositive status was an indepen-
dent and significant risk factor for
proteinuria in the general population,
with a summary estimate for adjusted
relative risk of 1.47 (95% confidence
interval (CI), 1.12–1.94; P¼ 0.006). Sig-
nificant heterogeneity occurred (propor-
tion of total variance due to between-
studies variance (Ri)¼ 0.82; P value by
Q-test, o0.001).2 Proteinuria clusters
with the metabolic syndrome, and sur-
veys have reported a relationship between
proteinuria and individual components
of the metabolic syndrome (insulin
resistance, hyperglycemia, dyslipidemia,
abdominal obesity, and arterial hyperten-
sion). Because patients with HCV are
known to have higher prevalence of
components of the metabolic syndrome,
it has been hypothesized that individuals
with HCV may have high frequency
of proteinuria. The persistence of the
relationship between HCV and protein-
uria after correction for several confoun-
ding parameters including metabolic
syndrome elements suggests the occur-
rence of HCV-associated cryoglobuli-
nemic or intrinsic renal disease.
The main clinical manifestations of
HCV-associated glomerular disease are
the presence of proteinuria and micro-
scopic hematuria with or without im-
paired kidney function. It has been
recommended by the Kidney Disease:
Improving Global Outcomes (KDIGO)
HCV guidelines that patients infected
with HCV be tested at least annually for
proteinuria, hematuria, and estimated
glomerular filtration rate (eGFR).3
HCV-infected patients with clinical
evidence of glomerulonephritis should
undergo kidney biopsy, and the out-
come of HCV-associated glomerulone-
phritis is improved by early diagnosis
and therapy. The routine laboratory
diagnosis of HCV-related glomerulone-
phritis is based on the presence of con-
ventional markers of HCV infection such
as anti-HCV antibody and HCV viremia
(HCV-RNA). The disappearance of
proteinuria after interferon therapy with
clearance of HCV-RNA from serum gives
emphasis to the pathogenetic activity of
HCV in this glomerular disease.3
Castillo et al.4 (this issue) have
hypothesized the role of occult HCV
infection in the development of HCV-
associated glomerular disease, occult
HCV being detectable viral RNA in
peripheral blood mononuclear cells or
in serum after ultracentrifugation in
anti-HCV-negative patients without
serum HCV-RNA. In their prospective
study on anti-HCV-negative/HCV-
RNA-negative patients, occult HCV
was more common in immune-media-
ted than hereditary glomerular disease,
39% (34/87) vs. 3.8% (1/26), P¼ 0.015.4
Occult HCV has been documented in
various populations, including hemo-
dialysis patients, patients with crypto-
genic hepatitis and liver cirrhosis,
hepatocellular carcinoma, lymphopro-
liferative disorders, and healthy indivi-
duals without evidence of liver disease
(Table 1).5 As shown in Table 1, the
frequency of occult HCV infection is
very heterogeneous, and differences in
the methods by which diagnosis of
occult HCV is made are probably an
important reason. The role played by
occult HCV infection in the pathogen-
esis of HCV-associated glomerular
disease is in agreement with some pieces
of evidence; as an example, interferon-
based therapy has given benefit in some
cases of HCV-negative cryoglobulinemic
glomerulonephritis. HCV antigens or
particles have been found in the kidney
tissue of patients with HCV-negative
glomerulonephritis. If confirmed, occult
HCV infection could be the underlying
cause of glomerular disease in some
patients with negative serologic viral
markers, and detection of occult HCV
might be the rationale for antiviral
therapy in anti-HCV-negative glomeru-
lar nephropathy.
The mechanisms of HCV-related
renal disease are uncertain, but research
suggests that HCV-associated glomeru-
lar injury results from deposition of
circulating immune complexes contain-
ing HCV proteins, anti-HCV antibody,
and rheumatoid factor IgM with anti-
IgG activity. Viral antigens have been
found by immunochemistry, and by
in situ hybridization. Some authors
have used laser microdissection to
detect HCV-RNA genomic sequences
of HCV core protein in glomeruli and
tubules of patients with HCV-asso-
ciated glomerular disease. Recently, an
elevation of toll-like receptor 3 (TLR3)
mRNA expression in glomeruli, parti-
cularly mesangial cells, of patients with
Table 1 |Occult hepatitis C virus infection in chronic kidney disease and other
patient groups
Authors Prevalence Study group
Reference
year
Barril et al.12 45% (49/109) Chronic hemodialysis 2008
Nicot et al.13 0% (0/26) Renal transplantation 2010
De Marco et al.14 1.27% (4/314) Infective liver disease-free patients 2009
Zaghloul & El-Sherbiny15 10% ((4/40) Chronic liver disease 2010
Idrees et al.16 74% (23/31) Cryptogenic liver disease 2011
Bokharaei-Salim et al.17 8.9% (4/45) Cryptogenic chronic liver disease 2011
Farahani et al.18 1.9% (2/104) Lymphoproliferative disorders 2013
Keyvani et al.19 8.9% (4/45) Cryptogenic cirrhosis 2013
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HCV-induced glomerulonephritis has
been seen, associated with an increased
activity of some proinflammatory
cytokines. A greater TLR3 expression
was observed in peripheral mononuc-
lear cells of patients with HCV-positive
glomerulonephritis (n¼ 46) compared
with HCV-negative patients (n¼ 32)
or healthy individuals (n¼ 20)
(Po0.0001).6 Another possible mecha-
nism underlying HCV-related glome-
rular disease is nonimmunologically
mediated—many studies have shown
a link between anti-HCV-positive
serologic status and increased insulin
resistance and hyperinsulinemia. Insu-
lin resistance and hyperinsulinemia can
give excess intrarenal production of
insulin-like growth factor-1 and trans-
forming growth factor-b, thus trigger-
ing proliferation of renal cells and
upregulation of the expression of an-
giotensin II type 1 receptors in mesan-
gial cells, which in turn enhances
oxidative activity at the kidney level.
The association between HCV
infection and the development or pro-
gression of kidney disease is more
controversial. Although the prevalence
of HCV is much higher among patients
with end-stage renal disease (ESRD)
than in the general population, it is
unknown whether this reflects an incre-
ased risk of viral exposure, a greater
incidence and progression of kidney
disease in individuals with HCV, or
both. The adverse impact of HCV
infection on the risk of developing
ESRD has been observed in diabetic
patients, in individuals with HIV and
HCV coinfection, and in cirrhotics who
completed interferon therapy. Crook
et al.7 identified 312 pre-ESRD patients
with diabetes mellitus (24 being anti-
HCV seropositive); Cox proportional
hazard analysis reported that anti-
HCV-seropositive status was a signifi-
cant and independent predictor of
ESRD after correction for multiple
independent parameters 3.49 (95% CI,
1.27–9.57; Po0.015). In the Women’s
Interagency HIV Study (n¼ 2684 HIV-
infected women), 180 women with HIV
and HCV coinfection and chronic
kidney disease at baseline (eGFR o60
ml/min per 1.73m2) had a greater fully
adjusted decline in eGFR over time
(–5.2% change per year; 95% CI, –3.2 to
–7.2; Po0.001) than HCV-seronegative
women.8 In the survey of Arase et al.,
650 patients with HCV-related cirrhosis
were followed up for a mean period of
6.5 years after completing interferon
therapy. Non-clearance of HCV was
linked to the development of chronic
kidney disease (eGFR o60ml/minper
1.73m2), adjusted hazard ratio 2.67
(95% CI, 1.34–5.32; P¼ 0.005).9
Additional data support a detrimen-
tal role of HCV in the development of
ESRD. Satapathy et al. retrospectively
evaluated 552 patients with serum
positive for antibody against HCV and
found that baseline high viral HCV
load (HCV-RNA 4700,000 copies/ml)
was an independent predictor of chronic
kidney disease (adjusted odds ratio, 2.45;
95% CI, 1.21–4.98; P¼ 0.01).10 In a
longitudinal study (4 years) on 111
patients with biopsy-proven glomerulo-
nephritis (21% being HCV positive),
Noureddine et al. found that HCV-
seropositive patients had a greater
risk of progression to ESRD than
HCV-negative individuals, according to
Cox regression analysis (adjusted hazard
ratio, 0.37; 95% CI, 0.19–0.76; Po0.05),
but this became non-significant after
adjustment for mean arterial pressure
and hemoglobin.11 In contrast, no
relationship between positive anti-HCV
serologic status and reduced GFR
(o60ml/min per 1.73m2) in the gene-
ral population (adjusted relative risk,
1.12; 95% CI, 0.91–1.38; P¼ 0.28) was
found in our pooled analysis of obser-
vational studies.2 We have updated
our systematic review of the published
medical literature; only longitudinal
studies (n¼ 7; 710,024 unique indivi-
duals) were retrieved. Pooling of study
results demonstrated a relationship bet-
ween HCV seropositivity and inci-
dence of reduced eGFR (adjusted rela-
tive risk, 1.70; 95% CI, 1.20–2.39;
P¼ 0.002); substantial heterogeneity
(proportion of total variance due to
between-studies variance (Ri)¼ 0.98;
P value by Q-test, o0.00001) without
publication bias was detected. The
heterogeneity among studies could be
related to occult HCV, in addition to
differences in the clinical and demo-
graphic characteristics of the study
populations, as well as the methods for
measuring renal impairment.
In conclusion, preliminary evidence
suggests a high frequency of occult
HCV infection in patients with glomer-
ular disease who are anti-HCVantibody
negative without serum HCV-RNA.
Further studies are needed to clarify
the epidemiology and significance of
occult HCV infection in patients with
glomerular disease. Standardization of
methods for detection of occult HCV
should be considered in future studies
on this subject.
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Pleiotropic effects of angiotensin
II blockers in hemodialysis
patients: myth or reality?
Carmine Zoccali1,2 and Francesca Mallamaci1,2
Mechanistic studies suggest that angiotensin II receptor blockers
(ARBs) may have pleiotropic effects on the cardiovascular system in
hemodialysis patients. A new randomized trial by Peters et al. failed
to show a benefit of irbesartan on biomarkers of arterial stiffness,
left ventricular mass, and autonomic nerve function. Their findings
suggest that, like in the general population and other disease states,
in hemodialysis patients the type of antihypertensive drug is unlikely
to be of major clinical relevance.
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The proportion of patients who die
of cardiovascular disease in stage 5
chronic kidney disease on dialysis
(5D-CKD) is almost identical to that
observed in the general population.1
However, due to the extremely high
mortality rate in 5D-CKD (at least
ten times higher than that in
the background general population),
in absolute terms the number of deaths
attributable to cardiovascular causes in
these patients is enormous. In contrast
with studies based on predialysis
blood pressure (BP), studies based on
24-hour ambulatory BP monitoring in
hemodialysis patients with no cardio-
vascular involvement or just moderate
cardiovascular involvement documen-
ted that 24-hour average systolic BP2
and nocturnal systolic BP3 are quite
strong predictors of death, emphasizing
the relevance of hypertension in the
high risk for cardiovascular death in
5D-CKD. Optimization of body fluid
balance by long and/or frequent hemo-
dialysis is the fundamental intervention
to control hypertension. However,
this intervention fails to normalize BP
in about 40% of cases. In the clinical
scenario, the hard reality is that anti-
hypertensive medications are used in
the vast majority of patients. In the face
of the widespread use of these drugs,
the number of randomized trials based
on meaningful clinical end points in
hypertensive hemodialysis patients is
very meager indeed. A meta-analysis by
Heerspink et al.4 in 2009 was based on
just eight trials, including a very small
study in patients on peritoneal dia-
lysis, two studies in patients with left
ventricular (LV) systolic dysfunction
or overt cardiac failure and normal or
low BP, and a trial that enrolled patients
with LV hypertrophy, independent
of BP. Subsequently, the Olmesartan
Clinical Trial in Okinawan Patients
Under OKIDS (OCTOPUS) trial in
hypertensive 5D-CKD patients was
published in 20135 and the Hyper-
tension in Hemodialysis Patients
Treated with Atenolol or Lisinopril
(HDPAL) trial in 2014.6 In all, only
five drug trials based on clinical end
points and specifically looking at the
treatment of hypertension in hemo-
dialysis patients have been performed.
Three of these trials, all performed in
Japan, tested angiotensin II receptor
blockers (ARBs) (Figure 1). In two of
these trials the risk of cardiovascular
events was remarkably lower (–47% and
–71%) in patients treated with ARBs,
while in the third trial, the largest
performed so far, no such benefit was
observed. A meta-analytical estimate
of the risk reduction by ARBs shows a
non-significant (P¼ 0.10) 42% risk
reduction, which seems to be comple-
tely independent of BP (Figure 1). Thus
the apparent beneficial effect of ARBs
in 5D-CKD apparently rests on the
pleiotropic effects of these drugs, a
hypothesis supported by the observation
that, independently of BP, telmisartan
reduced the death rate in hemodialysis
patients with chronic heart failure (New
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